Codeine
- Generic Name
- Codeine
- Brand Names
- Ascomp, Cheratussin, Cheratussin Dac, Codar Ar, Codar D, Codar Gf, Codeine Contin, Covan, Damylin With Codeine, Fioricet With Codeine, Histex Ac, Linctus Codeine Blanc, M-clear Wc, M-end PE, Mar-cof BP, Mar-cof Cg, Mersyndol, Ninjacof Xg, Pseudodine C, Robaxacet-8, Robaxisal, Triacin-C, Trianal C, Triatec, Triatec-30, Triatec-8, Tusnel C, Tuxarin, Tuzistra, Tylenol With Codeine
- Drug Type
- Small Molecule
- Chemical Formula
- C18H21NO3
- CAS Number
- 76-57-3
- Unique Ingredient Identifier
- UX6OWY2V7J
- Background
The relief of pain (analgesia) is a primary goal for enhancing the quality of life of patients and for increasing the ability of patients to engage in day to day activities. Codeine, an opioid analgesic, was originally approved in the US in 1950 and is a drug used to decrease pain by increasing the threshold for pain without impairing consciousness or altering other sensory functions. Opiates such as codeine are derived from the poppy plant, Papaver somniferum (Papaveraceae).
Codeine is utilized as a central analgesic, sedative, hypnotic, antinociceptive, and antiperistaltic agent, and is also recommended in certain diseases with incessant coughing.
- Indication
Codeine sulfate is a form of this drug that is commonly used. It is available in tablet form and indicated for the relief of mild to moderately severe pain, where the use of an opioid analgesic is appropriate .
The solution form is used by itself or combined in a syrup with other drugs and is used as a cough suppressant in adults aged 18 and above , .
- Associated Conditions
- Common Cold, Cough, Flu caused by Influenza, Mild pain, Pain, Severe Pain, Dry cough, Moderate Pain, Upper respiratory symptoms
- Associated Therapies
- Airway secretion clearance therapy
Open Label Study for the Functional Characterization of Drug Metabolism and Transport
- Conditions
- Genotype-related Drug Metabolism
- Interventions
- First Posted Date
- 2013-02-11
- Last Posted Date
- 2015-05-27
- Lead Sponsor
- Matthias Schwab
- Target Recruit Count
- 144
- Registration Number
- NCT01788254
- Locations
- 🇩🇪
Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany
🇩🇪Abteilung Klinische Pharmakologie, Tübingen, Germany
A Study of Oral Codeine Sulfate in Pediatric Patients With Post-procedural Pain
- First Posted Date
- 2012-08-31
- Last Posted Date
- 2018-10-02
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 31
- Registration Number
- NCT01676493
- Locations
- 🇺🇸
Children's Medical Center Dallas, Dallas, Texas, United States
Comparison of the Efficacy of Oral Oxycodone and Oral Codeine in the Treatment of Postcraniotomy Pain
- First Posted Date
- 2012-08-24
- Last Posted Date
- 2015-05-15
- Lead Sponsor
- Tan Tock Seng Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT01672112
- Locations
- 🇸🇬
Tan Tock Seng Hospital, Singapore, Singapore
Codeine in Mechanically Ventilated Neonates
- Conditions
- Mechanically Ventilated NeonatesPainful Procedures in Newborns
- Interventions
- First Posted Date
- 2011-03-24
- Last Posted Date
- 2018-08-27
- Lead Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- Target Recruit Count
- 6
- Registration Number
- NCT01322204
- Locations
- 🇺🇸
State University of New York Downstate, Brooklyn, New York, United States
Assessment of Opioid Analgesia in Sickle Cell
- Conditions
- Sickle Cell Disease
- Interventions
- First Posted Date
- 2007-08-09
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- Children's National Research Institute
- Registration Number
- NCT00513864
- Locations
- 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
Study Evaluating the Potential of DVS SR to Inhibit the CYP2D6 Pathway
- Conditions
- Depressive Disorder, MajorDiabetic NeuropathiesFibromyalgiaVasomotor Symptoms
- First Posted Date
- 2007-04-05
- Last Posted Date
- 2007-12-28
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 40
- Registration Number
- NCT00456898
Oxycodone or Standard Pain Therapy in Treating Patients With Cancer Pain
- Conditions
- PainUnspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2006-09-21
- Last Posted Date
- 2013-08-02
- Target Recruit Count
- 30
- Registration Number
- NCT00378937
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.